

**GynePlant: preliminary clinical experience with a copper and levonorgestrel releasing intrauterine system**

Wildemeersch D\*, Schacht E\*\*, Wildemeersch P\*.

\*Control Research, Ghent, Belgium

\*\*Polymer Research Group, University of Ghent, Department of Chemistry, Ghent, Belgium

**Abstract**

A novel intrauterine contraceptive drug delivery system derived from the conventional frameless (GyneFix) intrauterine implant system (IUS) is described and the results in 30 women are discussed. The first objective of the development of the GynePlant-levonorgestrel (LNG) system is to reduce menstrual bleeding by combining a shortened version of the standard GyneFix implant, having a copper surface area of 200 mm<sup>2</sup>, with a system for the sustained intrauterine delivery of levonorgestrel. The system releases 5 µg of LNG per day. The results of a pilot study using a LNG delivery system releasing 14 µg of LNG per day suggest that the GynePlant system, apart from being well tolerated, is safe and effective. The LNG-component appears to have a beneficial effect on the amount of bleeding. The results of the current study suggest that the GynePlant IUS, releasing 5 µg of LNG per day is effective in preventing pregnancy and to reduce or stabilize menstrual bleeding.